# Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer

> **NCT02646358** · PHASE1 · COMPLETED · sponsor: **Mast Therapeutics, Inc.** · enrollment: 27 (actual)

## Conditions studied

- Pharmacokinetics of Vepoloxamer
- Healthy Volunteers
- Renal Impaired

## Interventions

- **DRUG:** Vepoloxamer

## Key facts

- **NCT ID:** NCT02646358
- **Lead sponsor:** Mast Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2016-11
- **Final completion:** —
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2016-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02646358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02646358, "Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02646358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*